(MRVI) Maravai Lifesciences - Overview
Stock: Nucleic Acids, CleanCap, ELISA Kits, Custom Enzymes, Assay Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 73.2% |
| Relative Tail Risk | -15.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.28 |
| Alpha | -52.28 |
| Character TTM | |
|---|---|
| Beta | 1.318 |
| Beta Downside | 1.367 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.56% |
| CAGR/Max DD | -0.45 |
Description: MRVI Maravai Lifesciences January 21, 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a San Diego-based life-sciences tools provider that operates two core segments: Nucleic Acid Production and Biologics Safety Testing. The company supplies reagents, custom enzymes, messenger-RNA (mRNA) platforms, CleanCap capping technology, and oligonucleotide building blocks for gene-therapy, vaccine, and diagnostic applications, while its safety-testing line offers HCP ELISA kits, viral-clearance assays, and custom antibody development services for biopharmaceutical manufacturers.
In FY 2024 the firm reported a 22 % year-over-year revenue increase to $415 million, driven largely by expanding demand for mRNA-related reagents as vaccine and therapeutic pipelines mature. Gross margin improved to 58 % as the higher-value custom enzyme and CleanCap product lines scaled, and operating cash flow remained positive at $78 million, supporting ongoing R&D investment without dilutive financing.
Sector-wide, the global nucleic-acid therapeutics market is projected to grow at a CAGR of ~13 % through 2030, while regulatory pressure on biologics manufacturers to demonstrate impurity control fuels steady demand for ELISA-based safety testing kits. These macro trends underpin Maravai’s growth outlook, but execution risk remains around supply-chain constraints for specialty enzymes and competitive pressure from larger reagent vendors.
For a deeper, data-driven assessment of MRVI’s valuation metrics, you might explore the analytics platform ValueRay, which aggregates real-time financial and sector data to help pinpoint high-expected-value opportunities.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -121.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA -6.89 > 1.0 |
| NWC/Revenue: 137.5% < 20% (prev 222.4%; Δ -84.95% < -1%) |
| CFO/TA -0.06 > 3% & CFO -49.4m > Net Income -121.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (144.7m) vs 12m ago 2.21% < -2% |
| Gross Margin: 20.86% > 18% (prev 0.46%; Δ 2040 % > 0.5%) |
| Asset Turnover: 18.08% > 50% (prev 21.66%; Δ -3.59% > 0%) |
| Interest Coverage Ratio: -5.89 > 6 (EBITDA TTM -126.1m / Interest Expense TTM 31.7m) |
Altman Z'' 1.16
| A: 0.31 (Total Current Assets 325.9m - Total Current Liabilities 61.6m) / Total Assets 849.2m |
| B: 0.05 (Retained Earnings 45.8m / Total Assets 849.2m) |
| C: -0.18 (EBIT TTM -186.8m / Avg Total Assets 1.06b) |
| D: 0.12 (Book Value of Equity 48.9m / Total Liabilities 417.3m) |
| Altman-Z'' Score: 1.16 = BB |
Beneish M -1.97
| DSRI: 1.12 (Receivables 22.5m/28.9m, Revenue 192.3m/276.9m) |
| GMI: 2.22 (GM 20.86% / 46.36%) |
| AQI: 1.26 (AQ_t 0.43 / AQ_t-1 0.34) |
| SGI: 0.69 (Revenue 192.3m / 276.9m) |
| TATA: -0.08 (NI -121.2m - CFO -49.4m) / TA 849.2m) |
| Beneish M-Score: -1.97 (Cap -4..+1) = B |
What is the price of MRVI shares?
Over the past week, the price has changed by -9.91%, over one month by -18.47%, over three months by +7.67% and over the past year by -37.45%.
Is MRVI a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MRVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.9 | 27.2% |
| Analysts Target Price | 3.9 | 27.2% |
| ValueRay Target Price | 2 | -34.3% |
MRVI Fundamental Data Overview February 03, 2026
P/S = 6.3973
P/B = 1.9853
Revenue TTM = 192.3m USD
EBIT TTM = -186.8m USD
EBITDA TTM = -126.1m USD
Long Term Debt = 287.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.44m USD (from shortTermDebt, last quarter)
Debt = 35.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -207.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.02b USD (1.23b + Debt 35.8m - CCE 243.6m)
Interest Coverage Ratio = -5.89 (Ebit TTM -186.8m / Interest Expense TTM 31.7m)
EV/FCF = -15.43x (Enterprise Value 1.02b / FCF TTM -66.3m)
FCF Yield = -6.48% (FCF TTM -66.3m / Enterprise Value 1.02b)
FCF Margin = -34.49% (FCF TTM -66.3m / Revenue TTM 192.3m)
Net Margin = -63.05% (Net Income TTM -121.2m / Revenue TTM 192.3m)
Gross Margin = 20.86% ((Revenue TTM 192.3m - Cost of Revenue TTM 152.2m) / Revenue TTM)
Gross Margin QoQ = 13.58% (prev 16.39%)
Tobins Q-Ratio = 1.21 (Enterprise Value 1.02b / Total Assets 849.2m)
Interest Expense / Debt = 19.09% (Interest Expense 6.84m / Debt 35.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -147.5m (EBIT -186.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.29 (Total Current Assets 325.9m / Total Current Liabilities 61.6m)
Debt / Equity = 0.15 (Debt 35.8m / totalStockholderEquity, last quarter 245.4m)
Debt / EBITDA = 1.65 (negative EBITDA) (Net Debt -207.7m / EBITDA -126.1m)
Debt / FCF = 3.13 (negative FCF - burning cash) (Net Debt -207.7m / FCF TTM -66.3m)
Total Stockholder Equity = 284.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.40% (Net Income -121.2m / Total Assets 849.2m)
RoE = -42.64% (Net Income TTM -121.2m / Total Stockholder Equity 284.3m)
RoCE = -32.67% (EBIT -186.8m / Capital Employed (Equity 284.3m + L.T.Debt 287.4m))
RoIC = -25.50% (negative operating profit) (NOPAT -147.5m / Invested Capital 578.7m)
WACC = 10.89% (E(1.23b)/V(1.27b) * Re(10.77%) + D(35.8m)/V(1.27b) * Rd(19.09%) * (1-Tc(0.21)))
Discount Rate = 10.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.64%
Fair Price DCF = unknown (Cash Flow -66.3m)
EPS Correlation: -79.41 | EPS CAGR: -41.21% | SUE: 3.10 | # QB: 1
Revenue Correlation: -92.82 | Revenue CAGR: -36.49% | SUE: -1.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.05 | Chg30d=-0.001 | Revisions Net=-1 | Analysts=9
EPS next Year (2026-12-31): EPS=-0.21 | Chg30d=-0.004 | Revisions Net=-3 | Growth EPS=+32.9% | Growth Revenue=+9.8%